- Home
- IINN vs TVRD Comparison
IINN vs TVRD Comparison
Compare IINN & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IINN | TVRD |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 37.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | IINN | TVRD |
|---|---|---|
| Price | $0.94 | $3.89 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $2.00 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 174.4K | 135.5K |
| Earning Date | 10-01-2025 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $289,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,582.74 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $3.74 |
| 52 Week High | $1.65 | $43.65 |
Technical Indicators
Market Signals| Indicator | IINN | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 34.78 |
| Support Level | $0.92 | $3.90 |
| Resistance Level | $1.12 | $4.46 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | -0.01 | 0.14 |
| Stochastic Oscillator | 25.04 | 14.29 |
Price Performance
Historical ComparisonAbout IINN Inspira Technologies Oxy B.H.N. Ltd.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.